08:34 AM EST, 11/07/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that new long-term data on its drug Livdelzi showed consistent efficacy and safety in treating primary biliary cholangitis, including in patients who switched from obeticholic acid, with sustained improvements in liver stiffness over three years.

The company said the long-term study showed that 67% of participants achieved a composite biochemical response, and 34% reached normalized alkaline phosphatase levels after three years of treatment.

Gilead said that 85% of participants in its ongoing late-stage study maintained or improved liver stiffness after up to three years, with the highest-risk patients showing a median 29.7% reduction.

Additionally, data from the long-term study showed that Livdelzi produced sustained and meaningful reductions in chronic itch, a major symptom affecting up to 80% of patients, the company said.

Gilead said the improvements were maintained for up to 30 months, enhancing quality of life and daily functioning.

There were no treatment-related serious adverse events were reported, and no new safety signals emerged after up to four years of exposure, the company said.